Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/54277
Title: Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Authors: 
Filiation: Hospital Universitario 12 de Octubre
Mesh: 
Decs: 
Issue Date: 5-Apr-2018
Publisher: New England Journal of Medicine
Citation: N Engl J Med. 2018 Apr;(378)14:1277-1290
Abstract: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.
PMID: 29562145
URI: https://hdl.handle.net/20.500.12530/54277
Rights: info:eu-repo/semantics/openAccess
ISSN: 0028-4793
Appears in Collections:Hospitales > H. U. 12 de Octubre > Artículos

Files in This Item:
File Description SizeFormat 
29562145.pdf403,1 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.